Search
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalBoth can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]
Panax ginseng fruit
go.drugbank.com/drugs/DB14261InvestigationalPanax ginseng fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Panax Verus Fruit, Panax ginseng fruitPanax quinquefolius whole
go.drugbank.com/drugs/DB14296InvestigationalPanax quinquefolius whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Panax Quinquefolius, Panax Quinquefolium WholePanax notoginseng root
go.drugbank.com/drugs/DB14304InvestigationalPanax notoginseng root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Panax notoginseng root, Panax Notoginseng Root ExtractErythromycin
go.drugbank.com/drugs/DB00199ApprovedInvestigationalVet approved[L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. … Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIt was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnThe manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms.